CR20210336A - Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina - Google Patents

Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina

Info

Publication number
CR20210336A
CR20210336A CR20210336A CR20210336A CR20210336A CR 20210336 A CR20210336 A CR 20210336A CR 20210336 A CR20210336 A CR 20210336A CR 20210336 A CR20210336 A CR 20210336A CR 20210336 A CR20210336 A CR 20210336A
Authority
CR
Costa Rica
Prior art keywords
imidazopyridazine
inhibitors
compounds
receptor kinase
activin receptor
Prior art date
Application number
CR20210336A
Other languages
English (en)
Inventor
Wenqing Yao
Jeremy Roach
Song Mei
Chunhong He
Liangxing Wu
Jun Pan
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CR20210336A publication Critical patent/CR20210336A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos de Fórmula (I), métodos para usar los compuestos para inhibir la actividad de ALK2 y composiciones farmacéuticas que comprenden tales compuestos. Los compuestos son útiles para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de ALK2, como el cáncer.
CR20210336A 2018-12-20 2019-12-19 Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina CR20210336A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782994P 2018-12-20 2018-12-20
US201962935891P 2019-11-15 2019-11-15
PCT/US2019/067403 WO2020132197A1 (en) 2018-12-20 2019-12-19 Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Publications (1)

Publication Number Publication Date
CR20210336A true CR20210336A (es) 2021-12-06

Family

ID=69467674

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210336A CR20210336A (es) 2018-12-20 2019-12-19 Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina

Country Status (20)

Country Link
US (3) US11459329B2 (es)
EP (1) EP3898627A1 (es)
JP (2) JP7414827B2 (es)
KR (1) KR20210116488A (es)
CN (2) CN120208959A (es)
AU (1) AU2019401649B2 (es)
BR (1) BR112021011948A2 (es)
CA (1) CA3124088A1 (es)
CL (1) CL2021001656A1 (es)
CO (1) CO2021008117A2 (es)
CR (1) CR20210336A (es)
EC (1) ECSP21044843A (es)
IL (2) IL284139B2 (es)
MA (1) MA54551A (es)
MX (1) MX2021007426A (es)
PE (1) PE20220277A1 (es)
PH (1) PH12021551446A1 (es)
SG (1) SG11202106582YA (es)
TW (2) TWI852968B (es)
WO (1) WO2020132197A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019401649B2 (en) 2018-12-20 2025-08-28 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
WO2021222875A1 (en) 2020-04-30 2021-11-04 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
AR122587A1 (es) * 2020-06-12 2022-09-21 Incyte Corp Compuestos de imidazopiridazina y sus usos
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2023066204A1 (zh) * 2021-10-18 2023-04-27 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
SI1283839T1 (es) 2000-05-26 2005-08-31 Schering Corp
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
JP2005343889A (ja) * 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
ES2354824T3 (es) * 2004-11-04 2011-03-18 Vertex Pharmaceuticals, Inc. Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas.
ES2560435T3 (es) * 2006-11-22 2016-02-19 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
PE20090506A1 (es) 2007-07-26 2009-05-28 Novartis Ag DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
MX2010004244A (es) * 2007-10-17 2010-04-30 Novartis Ag Derivados de imidazo [i,2-a]-piridina utiles como inhibidores de cinasa tipo activina (alk).
CA2805033A1 (en) * 2009-07-14 2011-01-20 Beth Israel Deaconess Medical Center, Inc. Methods of increasing liver proliferation
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
ES2539257T3 (es) * 2010-07-28 2015-06-29 Bayer Intellectual Property Gmbh Imidazo[1,2-b]piridazinas sustituidas
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
CA2834901A1 (en) 2011-05-06 2012-11-15 Bayer Intellectual Property Gmbh Substituted imidazopyridines and imidazopyridazines and the use thereof
EP2900238B1 (en) * 2012-09-28 2017-12-06 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
MX2015005375A (es) * 2012-11-07 2015-07-21 Hoffmann La Roche Compuestos de triazolo.
US9682983B2 (en) * 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
MY199705A (en) 2015-12-22 2023-11-20 Incyte Corp Heterocyclic compounds as immunomodulators
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
KR102685249B1 (ko) 2016-06-20 2024-07-17 인사이트 코포레이션 면역조절제로서의 복소환식 화합물
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
EP3854796A1 (en) * 2016-08-17 2021-07-28 Children's Hospital Medical Center Imidazo[1,2-a]pyridine compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
JP2019533643A (ja) * 2016-09-14 2019-11-21 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ Ｂｍｐシグナル伝達の阻害、その化合物、組成物および使用
MX2019002951A (es) 2016-09-15 2019-09-11 Armstrong World Ind Inc Sistema de techo con movimiento aereo.
PE20191532A1 (es) 2016-12-22 2019-10-23 Incyte Corp Compuestos heterociclicos como inmunomoduladores
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119224A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
BR112019014759A2 (pt) 2017-01-18 2020-03-03 Vanderbilt University Compostos heterocíclicos fundidos como inibidores seletivos de bmp
WO2018165569A1 (en) * 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
WO2018166493A1 (zh) 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
SG11201908940UA (en) * 2017-03-30 2019-10-30 Hoffmann La Roche Isoquinolines as inhibitors of hpk1
MX2020004190A (es) 2017-10-24 2020-08-03 Bayer Ag Amidas de imidazopiridina sustituidas y su uso.
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
AU2019401649B2 (en) 2018-12-20 2025-08-28 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
AR122587A1 (es) 2020-06-12 2022-09-21 Incyte Corp Compuestos de imidazopiridazina y sus usos

Also Published As

Publication number Publication date
TW202039502A (zh) 2020-11-01
CN120208959A (zh) 2025-06-27
US11459329B2 (en) 2022-10-04
CA3124088A1 (en) 2020-06-25
JP7414827B2 (ja) 2024-01-16
AU2019401649A1 (en) 2021-07-08
US20220315595A1 (en) 2022-10-06
MA54551A (fr) 2021-10-27
IL284139B2 (en) 2025-06-01
PE20220277A1 (es) 2022-02-25
WO2020132197A1 (en) 2020-06-25
JP2024045155A (ja) 2024-04-02
CL2021001656A1 (es) 2021-12-17
CO2021008117A2 (es) 2021-09-20
BR112021011948A2 (pt) 2021-09-08
SG11202106582YA (en) 2021-07-29
US20240309008A1 (en) 2024-09-19
CN114787160B (zh) 2025-03-25
KR20210116488A (ko) 2021-09-27
JP2022514650A (ja) 2022-02-14
TW202504901A (zh) 2025-02-01
IL284139B1 (en) 2025-02-01
JP7723068B2 (ja) 2025-08-13
US20200199131A1 (en) 2020-06-25
CN114787160A (zh) 2022-07-22
AU2019401649B2 (en) 2025-08-28
IL284139A (en) 2021-08-31
US12030889B2 (en) 2024-07-09
IL318278A (en) 2025-03-01
PH12021551446A1 (en) 2021-12-06
TWI852968B (zh) 2024-08-21
EP3898627A1 (en) 2021-10-27
MX2021007426A (es) 2021-09-08
ECSP21044843A (es) 2021-09-30

Similar Documents

Publication Publication Date Title
ECSP21044843A (es) Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
ECSP20060827A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
MX2018012609A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
CL2022000457A1 (es) Triazolopirimidinas como inhibidores de a2a/a2b.
ECSP18014798A (es) Inhibidores de ezh2
MX2017007114A (es) Una triazolopiridazina como un modulador de cinasa.
CO2022017969A2 (es) Compuestos de imidazopiridazina con actividad como inhibidores de alk2
AR117459A1 (es) Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras
EA202191738A1 (ru) Соединения имидазопиридазина и имидазопиридина и их применение
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores
CU20100038A7 (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos